Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide, and epirubicin

Ph Collard, P Weynants, Ch Francis, D O Rodenstein

Abstract

Background Relapse of small cell lung cancer is not usually treated with further chemotherapy as results are considered to be disappointing.

Methods and results Six patients with relapse of small cell lung cancer after a complete initial response and remission of more than one year responded to repeat treatment with the initial chemotherapy comprising carboplatin, etoposide, and epirubicin. The second remission ranged from six months to more than 15 months.

Conclusion In patients with a relapse of small cell lung cancer after a complete initial response and prolonged remission retreatment with the initial combination chemotherapy cannot be dismissed and requires further study.

Small cell lung cancer has an aggressive course and is usually widespread at presentation. Surgery has been advocated in truly limited disease, but this is rare.1 The best therapeutic approach for the time being is chemotherapy. Several combination regimens administered over three to six months have improved median survival and there is at present no clear advantage for any particular regimen.2 Unfortunately, the disease usually relapses a few months after discontinuation of chemotherapy and the benefit of further treatment at this stage is less clear.

We report six patients with disease relapse who showed a good response to a repeat course of chemotherapy with the initial drug regimen of carboplatin, etoposide, and epirubicin.3

Case reports

From January 1987 to December 1990 small cell lung cancer was diagnosed in 78 patients, 36 with limited disease and 42 with extensive disease. All were treated with intravenous carboplatin 330 mg/m² and epirubicin 60 mg/m² on day 1 and intravenous etoposide 120 mg/m² on days 1, 3, and 5; courses were separated by three week intervals. The effect of the carboplatin-etoposide-epirubicin regimen was not assessed in 15 patients as they received less than two courses of chemotherapy. Of the remaining 63 patients, six were non-responders, 33 partial responders, and 24 complete responders (18 of whom had limited disease at initial staging); in most of the complete responders chemotherapy was followed by radiotherapy to the primary tumour mass (60 Gy) and the mediastinum (50 Gy), and they also received prophylactic cranial irradiation (30 Gy). Of the 24 complete responders, 12 relapsed early (less than 12 months after stopping treatment) and seven had a late relapse (all had had limited disease initially); five patients have not yet relapsed. The patients with a late relapse were treated with further courses of carboplatin-etoposide-epirubicin and are described in this paper.

The clinical characteristics and the response to treatment of six of the patients are summarised in the table. Clinical tolerance to chemotherapy was excellent in all cases and no febrile episodes occurred; patient 2 required an occasional blood transfusion during chemotherapy. The six patients experienced considerable improvement in symptoms and gained weight after repeat treatment with carboplatin-etoposide-epirubicin; patients 1 and 3 returned to sedentary work for several months while in their second remission.

Data on the patients

<table>
<thead>
<tr>
<th>Patient No:</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, age (y)</td>
<td>M, 57</td>
<td>F, 59</td>
<td>M, 62</td>
<td>F, 62</td>
<td>M, 60</td>
<td>F, 71</td>
</tr>
<tr>
<td>Initial extension</td>
<td>Limited</td>
<td>Limited</td>
<td>Limited</td>
<td>Limited</td>
<td>Limited</td>
<td>Limited</td>
</tr>
<tr>
<td>Initial treatment</td>
<td>4 Cx, LI, CI</td>
<td>6 Cx, CI</td>
<td>6 Cx, LI, CI</td>
<td>6 Cx, LI, CI</td>
<td>6 Cx, LI, CI</td>
<td>6 Cx, CI</td>
</tr>
<tr>
<td>First response</td>
<td>Complete</td>
<td>Complete</td>
<td>Complete</td>
<td>Complete</td>
<td>Complete</td>
<td>Complete</td>
</tr>
<tr>
<td>Remission (months)</td>
<td>19</td>
<td>17</td>
<td>22</td>
<td>31</td>
<td>21</td>
<td>29</td>
</tr>
<tr>
<td>Relapse site</td>
<td>Local and brain</td>
<td>Local</td>
<td>Local</td>
<td>Local</td>
<td>Local</td>
<td>Local and liver</td>
</tr>
<tr>
<td>Relapse treatment</td>
<td>6 Cx</td>
<td>6 Cx</td>
<td>4 Cx</td>
<td>4 Cx</td>
<td>4 Cx</td>
<td>4 Cx</td>
</tr>
<tr>
<td>Second response</td>
<td>Complete</td>
<td>Complete</td>
<td>Partial</td>
<td>Partial</td>
<td>Partial</td>
<td>Partial</td>
</tr>
<tr>
<td>Remission (months)</td>
<td>10</td>
<td>11</td>
<td>6</td>
<td>12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Final relapse site</td>
<td>Brain</td>
<td>Brain</td>
<td>Brain</td>
<td></td>
<td>Local and liver</td>
<td></td>
</tr>
<tr>
<td>Survival (months)</td>
<td>32</td>
<td>28</td>
<td>28</td>
<td>51</td>
<td>&gt; 36</td>
<td>&gt; 36</td>
</tr>
</tbody>
</table>

Cs—polychemotherapy course with carboplatin, etoposide, and epirubicin; LI—local irradiation; CI—cranial irradiation.
The seventh patient, with a late relapse of small cell lung cancer, developed left lung atelectasis from an occluded main bronchus 15 months after achieving a complete response from carboplatin-etoposide-epirubicin induction treatment. He was treated again with carboplatin-etoposide-epirubicin but died after a single course from an infected perineal haematoma (presumably facilitated by the chemotherapy induced pancytopenia). There was already an objective response to the repeat treatment, with evidence of aeration of the left lung; he survived for 23 months after diagnosis.

**Discussion**

A four to eight course induction chemotherapy regimen is regarded as standard initial treatment for small cell lung cancer. Most studies have shown that maintenance or late intensification treatment does not provide...
appreciable survival advantage and may in fact be deleterious in terms of quality of life. With modern induction treatment a complete response is achieved in a growing number of patients, who subsequently enjoy several months of good quality remission.

Treatment policy on relapse is controversial and many patients and physicians are reluctant to consider further chemotherapy. A recent editorial states that further chemotherapy after the induction phase is not useful and that survival is not improved. It is also widely believed that if further treatment is prescribed it should be based on drugs other than those used in the induction regimen. When a patient has shown a complete response to induction treatment we have elected to use the same treatment for relapse. As these cases show, we have had encouraging results with minimal toxicity. So far we have observed a response to relapse treatment with carboplatin-etoposide-epirubicin in every patient meeting the conditions of a complete initial response and a prolonged first remission of at least 12 months after finishing induction treatment.

A further course of induction treatment has proved effective in other malignancies, such as breast cancer, ovarian cancer, multiple myeloma, and Hodgkin’s disease. A few studies have indicated that further treatment with the initial chemotherapeutic regimen may be effective in patients with small cell lung cancer who relapse after a short induction course. The response to initial treatment, the length of remission, and performance status may have prognostic significance in this context. As in our cases, the complete response rate and duration of remission tend to be shorter after reinduction chemotherapy than after the initial treatment. The carboplatin-etoposide-epirubicin chemotherapy appeared to be active against disease at other sites, including cerebral metastases (table and figs 1–3), as has been found with initial treatment.

In contrast to the results in these patients, the response rate with salvage treatment (whether carboplatin-etoposide-epirubicin; an alternative chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and methotrexate; or radiotherapy) has been very poor in our hands for patients with an initial partial response or short term remission after complete response to induction treatment with carboplatin-etoposide-epirubicin.

Although a definite policy on relapse treatment will be arrived at only after large scale randomised trials, our preliminary experience suggests that using the same carboplatin-etoposide-epirubicin chemotherapy regimen for relapse in small cell lung cancer may be an effective (albeit palliative) treatment provided that the initial response was complete and the first remission was prolonged.

Although the response to chemotherapy at relapse is disappointing for most patients with small cell lung cancer, identifying patients likely to derive benefit from repeated chemotherapy is important, in terms both of survival and of quality of life. The subgroup we have defined represents about 10% of patients with small cell lung cancer. If our findings are confirmed in a larger number of patients, with similar characteristics, the current policy of no further treatment after relapse will need to be revised so that patients will not be denied a potentially useful and well tolerated treatment.

We thank Dr Y Humblet for his useful comments on the manuscript.